Fig. 4.
Fig. 4. Bcl-xL overexpression inhibits caspases-2, -3, -6, -7, -8, and -10 and Bid activation induced by ELL-12 in Jurkat cells. Cytosolic extracts from Jurkat/neo or Jurkat/Bcl-xLcells treated for 5 hours without or with 10 μg/mL ELL-12 were subjected to SDS-PAGE and immunoblotted with anti–caspase-3 (A), anti–caspase-7 (B), anti-PARP (C), anti–caspase-6 (D), anti-lamin B (E), anti–caspase-2 (F), anti–caspase-8 (G), anti–caspase-10 (H), or anti-Bid (I). The migration position of full-length caspase-3, cleavage intermediate p20, active subunit p17, full-length caspase-7, active subunit p20, full-length PARP, cleaved forms p89 and p24, full-length caspase-6, full-length lamin B, cleaved form p28, full-length caspase-2, active form p12, full-length caspase-8, cleavage intermediates p43 and p41, active subunit p18, full-length caspase-10, cleavage intermediate p23, active subunit p17, and full-length Bid are indicated.

Bcl-xL overexpression inhibits caspases-2, -3, -6, -7, -8, and -10 and Bid activation induced by ELL-12 in Jurkat cells. Cytosolic extracts from Jurkat/neo or Jurkat/Bcl-xLcells treated for 5 hours without or with 10 μg/mL ELL-12 were subjected to SDS-PAGE and immunoblotted with anti–caspase-3 (A), anti–caspase-7 (B), anti-PARP (C), anti–caspase-6 (D), anti-lamin B (E), anti–caspase-2 (F), anti–caspase-8 (G), anti–caspase-10 (H), or anti-Bid (I). The migration position of full-length caspase-3, cleavage intermediate p20, active subunit p17, full-length caspase-7, active subunit p20, full-length PARP, cleaved forms p89 and p24, full-length caspase-6, full-length lamin B, cleaved form p28, full-length caspase-2, active form p12, full-length caspase-8, cleavage intermediates p43 and p41, active subunit p18, full-length caspase-10, cleavage intermediate p23, active subunit p17, and full-length Bid are indicated.

Close Modal

or Create an Account

Close Modal
Close Modal